<DOC>
	<DOCNO>NCT01309789</DOCNO>
	<brief_summary>The purpose study assess safety profile brentuximab vedotin sequentially combination multi-agent chemotherapy front-line treatment CD30-positive mature T-cell NK-cell neoplasm , include systemic anaplastic large cell lymphoma . It phase 1 , open-label , dose escalation study three arm design define MTD , PK , immunogenicity , anti-tumor activity brentuximab vedotin sequence combination multi-agent front-line chemotherapy .</brief_summary>
	<brief_title>A Phase 1 Study Brentuximab Vedotin Given Sequentially Combined With Multi-Agent Chemotherapy CD30-Positive Mature T-Cell NK-Cell Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Treatmentnaive CD30positive mature Tcell NKcell neoplasms , include systemic anaplastic large cell lymphoma Measurable disease least 1.5 cm ECOG performance status less equal 2 Known cerebral/meningeal disease , include history progressive multifocal leukoencephalopathy Current diagnosis primary cutaneous anaplastic large cell lymphoma , mycosis fungoides , Sezary syndrome primary cutaneous lymphoma ; extranodal NK/Tcell lymphoma , nasal type History another primary malignancy remission least 3 year Left ventricular ejection fraction &lt; 45 % symptomatic cardiac disease , myocardial infarction within past 12 month Viral , bacterial , fungal infection within two week prior first dose brentuximab vedotin Known human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus positive status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Lymphoma , T-cell</keyword>
	<keyword>Lymphoma , NK-cell</keyword>
</DOC>